A further systematic review comparing metformin vs. insulin/sulphonylureas also demonstrated a reduced risk of HCC with metformin, with an OR of 0.47 (CI: 0.28–0.80), which was not seen with the other therapies [103]. Here, INS is linked to hepatocellular carcinoma.